August 6, 2020 GREAT NEWS!!!

August 6, 2020, Rafael Pharmaceuticals announced that they had reached the goal of enrolling 500 patients into their phase three study of CPI613 (devimistat) plus modified Folfirinox in the treatment of Stage 4 Pancreatic Cancer. I also hear that the recruiting process took about a year and a half less than was expected. Congratulations Rafael Pharmaceuticals!!!!!!

See this article: https://www.globenewswire.com/news-release/2020/08/06/2074264/0/en/Rafael-Pharmaceuticals-Achieves-Target-Enrollment-of-500-Patients-in-Pivotal-Phase-3-Trial-AVENGER-500-of-CPI-613-%EF%B8%8F-devimistat-for-Patients-with-Metastatic-Pancreatic-Cancer.html

CPI613 can still be made available through compassionate use. Have your doctor download and fill out the forms. And other options can be found at PanCan.